MLICM
PCVX icon

Metropolitan Life Insurance Company (MetLife)’s Vaxcyte PCVX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,573
Closed -$381K – 1522
2024
Q1 		$381K Buy
5,573
+252
+5% +$17.4K 0.02% 523
2023
Q4 		$334K Sell
5,321
-117
-2% -$6.08K 0.02% 551
2023
Q3 		$277K Buy
5,438
+418
+8% +$20.6K 0.01% 569
2023
Q2 		$251K Buy
5,020
+1,042
+26% +$49.4K 0.01% 590
2023
Q1 		$149K Sell
3,978
-453
-10% -$19.2K 0.01% 790
2022
Q4 		$212K Buy
4,431
+1,237
+39% +$48.5K 0.01% 685
2022
Q3 		$76.7K Hold
3,194
– – ﹤0.01% 1175
2022
Q2 		$69.5K Buy
3,194
+520
+19% +$12K ﹤0.01% 1295
2022
Q1 		$64.6K Sell
2,674
-8,743
-77% -$191K ﹤0.01% 1449
2021
Q4 		$272K Hold
11,417
– – ﹤0.01% 1801
2021
Q3 		$290K Hold
11,417
– – ﹤0.01% 1801
2021
Q2 		$257K Buy
11,417
+2,861
+33% +$58.6K ﹤0.01% 1970
2021
Q1 		$169K Buy
8,556
+3,159
+59% +$79.5K ﹤0.01% 2143
2020
Q4 		$143K Hold
5,397
– – ﹤0.01% 2164
2020
Q3 		$267K Buy
+5,397
New +$215K ﹤0.01% 1600

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s PCVX Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Vaxcyte (PCVX) in Q2 2024, closing a stake of 5,573 shares — an estimated $381K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in PCVX in Q3 2020 and held it in 15 quarters. The position peaked at $381K in Q1 2024. 265 funds tracked by Wall St. Rank hold PCVX as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Vaxcyte position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 5,573 Vaxcyte shares in Q2 2024, an estimated $381K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Vaxcyte in Q3 2020 and held it in 15 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Vaxcyte position peaked at $381K in Q1 2024.
  • 265 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.